MASTERCOW, an antibiotic-free bioinorganic therapy for bovine mastitis

Información del proyecto

MASTERCOW

Identificador del acuerdo de subvención: 826673

DOI

10.3030/826673

Proyecto cerrado

Fecha de la firma de la CE 17 Julio 2018

Fecha de inicio 1 Agosto 2018

Fecha de finalización 31 Enero 2019

Financiado con arreglo a

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Coste total

€ 71 429,00

Aportación de la UE

€ 50 000,00

Coordinado por

CNT LAB SRL
Italy

Periodic Reporting for period 1 - MASTERCOW (MASTERCOW, an antibiotic-free bioinorganic therapy for bovine mastitis)

Período documentado: 2018-08-01 hasta 2019-01-31

Resumen del contexto y de los objetivos generales del proyecto

Bovine Mastitis is a relevant problem in dairy industry and current therapies based upon antibiotics may cause several side effects, from different perspective:
• Animal welfare: cows suffer, they need to be separate from other animals in 1/3 cases, the mastitis becomes chronic and causes death ;
• Mastitis therapy may cause several economic damages: milk is discarded for at least 15 days and the cost of antibiotics and veterinaries may rise up to 400€ per heard
• Antibiotics may compromise safety of milk, since residual may have side effect for human health, causing food intolerance and allergies.
CNT LAB has developed an innovative treatment for bovine mastitis that it is not based on antibiotics and can cure dairy cows in less time, with an higher success rate and at 10% of overall costs.
The PH1 project aimed at validating the product concept on the market and at fine tuning the distribution strategy by identifying the right commercial partners in addressed markets. A small pilot project has been run, to validate MASTERCOW approach.

Trabajo realizado desde el comienzo del proyecto hasta el final del período abarcado por el informe y los principales resultados hasta la fecha

In PH1 project we achieved following objectives
• description of main problem;
• market analysis: structural features of target markets
• market validation study (i.e. contact with potential distributors);
• technical validation through small pilot project
• definition of a preliminary P&L account

Avances que van más allá del estado de la técnica e impacto potencial esperado (incluida la repercusión socioeconómica y las implicaciones sociales más amplias del proyecto hasta la fecha)

CNTLAB, the SME proposers, has developed a totally new approach in bovine mastitis therapy: MASTERCOW. Unlike antibiotics which can be ineffective and carry the risk of resistance, MASTERCOW allow to achieve a strongly increased cure rate (from 70% up to 90%), with a lower cost, decreased therapy duration ensuring wellbeing of the cow.
EFSA (European Food Safety Authority) calls for actions to protect consumers from risks related to the food chain. When antimicrobial resistance occurs in zoonotic bacteria present in animals and food it can also compromise the effective treatment of infectious diseases in humans.
MASTERCOW project contributes to the implementation of these policies willing to provide on the market a more effective solutions for mastitis, without the use of conventional antibiotics. In doing this, the animal welfare is seriously considered: the EU has among the world’s highest standards of animal welfare

mastecow.jpg